Search results
Showing 16 to 30 of 38 results for lenvatinib
Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)
Evidence-based recommendations on selective internal radiation therapies SIR-Spheres (Sirtex), TheraSphere (BTG) and QuiremSphere (Quirem Medical) for treating hepatocellular carcinoma in adults.
Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)
Evidence-based recommendations on cabozantinib (Cabometyx) for advanced hepatocellular carcinoma in adults who have had sorafenib.
Awaiting development Reference number: GID-TA11751 Expected publication date: TBC
Awaiting development Reference number: GID-TA11653 Expected publication date: TBC
In development Reference number: GID-TA11584 Expected publication date: 08 December 2027
Discontinued Reference number: GID-TA10811
Discontinued Reference number: GID-TA10697
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)
Evidence-based recommendations on avelumab (Bavencio) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.
Discontinued Reference number: GID-TA11008
Evidence-based recommendations on dostarlimab (Jemperli) with platinum-based chemotherapy for primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults.
Show all sections
Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]
Discontinued Reference number: GID-TA11020
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]
Discontinued Reference number: GID-TA10851
Discontinued Reference number: GID-TA10880
Discontinued Reference number: GID-TA11005